|Nom||Titre||Payer||Exercé||Année de naissance|
|Mr. Remi Barbier||Founder, Chairman, Pres & CEO||1,11M||297,42k||1960|
|Mr. Eric J. Schoen||Chief Financial Officer||426,61k||S.O.||1968|
|Mr. R. Christopher Cook||Sr. VP, Company Sec. & Gen. Counsel||457,64k||S.O.||1964|
|Dr. James W. Kupiec M.D.||Chief Medical Officer||400k||S.O.||1953|
|Dr. George Thornton||Sr. VP of Technology||S.O.||S.O.||S.O.|
|Mr. Michael Zamloot||Sr. VP of Technical Operations||S.O.||S.O.||S.O.|
|Dr. Michael Marsman Pharm.D.||Sr. VP of Regulatory Affairs||S.O.||S.O.||S.O.|
|Dr. Lindsay H. Burns Ph.D.||Sr. VP of Neuroscience||S.O.||S.O.||S.O.|
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
L’ISS Governance QualityScore de Cassava Sciences, Inc. en date du 1 septembre 2023 est 10. Les scores principaux sont Audit : 10; Société : 10; Droits des actionnaires : 8; Compensation : 8.